Nanobubbles: a promising efficient tool for therapeutic delivery of antibacterial agents for the Staphylococcus aureus infections.

The current research is focused to address the implementation of nanobubbles technology to antibacterial agents against Staphylococcus aureus infections. Nanobubbles technology is a novel, latest research employed in many medical fields including drug discovery. In this present work, supramolecular nanoliquid formulation of potential antiseptic agent chloroxylenol-based Dettol and its enhanced antibacterial activity, biocompatibility assessment was studied. Nanobubble technology was adopted to prepare nanoformulation (NB-D) using a household hand mixer under thermostatically controlled conditions. A high-stability nanoformulation with high potential antibacterial activity against human pathogenic strains of Pseudomonas aeruginosa and Staphylococcus aureus was produced by the nanobubbles created in the antiseptic solution. The overall vitality of both strains was significantly reduced in all dose tests on NB-D treatment as a result of the antibacterial activity as assessed by the well-diffusion assay, turbidometric microdilution assay, biofilm inhibition assay, and total count reduction assay. Biocompatibility of the NB-D formulation was studied by the determination of cytotoxicity against HaCaT-human keratinocytes and hemocytes. NB-D treatment did not induce any notable cytotoxic effect on HaCaT cells by showing none of the changes in cell morphology and architecture. No toxic effect on the hematocytes was observed in NB-D treatment. The enhanced antibacterial activity and best biocompatibility of NB-D result shows that the nanobubble technology could be used as an effective strategy for the formulation of antiseptics or disinfectants against high health risk infectious organisms. The novelty of the work is the formation of supramolecular nanoformulation on antiseptic agent which promised the results enhanced than the raw antiseptic agent.